With its innovative Clinical Trials Network, influential annual meeting and high-impact journals, SNMMI encourages and facilitates research and science for the nuclear medicine and molecular imaging field. Learn more.

Clinical Trials Network

The Clinical Trials Network (CTN) provides tools and resources to promote faster, more cost-effective drug development and increase the availability and performance of molecular imaging radiopharmaceuticals for use in the clinic. Our Mission is to advance the use of molecular imaging agents in clinical trials through standardization of chemistry and imaging methodology. This includes using imaging radiopharmaceuticals during the course of drug development, as well as bringing new radiopharmaceuticals to regulatory approval. Programs developed over the past 5 years include a comprehensive registry of qualified imaging sites and radiopharmaceutical manufacturers, a robust scanner validation program, access to standardized imaging protocols and a very strong clinical research education curriculum.


  • May 4, 2018FDA Issues Updated Guidance on Clinical Trial Imaging Standards
    The U.S. Food and Drug Administration (FDA) has issued an updated guidance for the standardization of imaging data collected and managed as part of clinical trials. While considerable standardization already exists in clinical imaging, the new guidance recommends additional trial-specific imaging process standards.
  • May 3, 2018PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis
    A novel PET tracer developed by Korean researchers can visualize joint inflammation and could provide early diagnosis of rheumatoid arthritis, a common autoimmune disease that causes chronic inflammation of joints and can lead to deformity and dysfunction. The study is reported in the featured basic science article in The Journal of Nuclear Medicine’s May issue.
  • May 1, 2018Novel Theranostic Approach for Treating Pancreatic Cancer Patients Shows Promise
    German researchers have developed a novel diagnostic and therapeutic (theranostic) procedure for patients with ductal pancreatic adenocarcinoma, a deadly cancer with an extremely poor prognosis (five-year survival rate of less than 5 percent) and limited treatment options. The study is featured in the May issue of The Journal of Nuclear Medicine.
  • April 6, 2018PET Tracer Could Help Predict Treatment Effectiveness for Depression
    A PET imaging agent could show, ahead of time, whether a specific treatment is likely to be effective for major depressive disorder—a debilitating condition that affects more than 14 million Americans. No such marker is currently available in clinical psychiatry. The study is featured in the April issue of The Journal of Nuclear Medicine.
  • April 2, 2018Novel PET Imaging Agent Could Help Guide Therapy for Brain Diseases
    Researchers have developed a new PET imaging agent that could help guide and assess treatments for people with various neurological diseases, including Alzheimer’s, Parkinson’s, and multiple sclerosis. The agent targets receptors in nerve cells in the brain that are involved in learning and memory. The study is featured in the April issue of The Journal of Nuclear Medicine.
  • March 31, 2018Happy Birthday RAI!
    On this day in 1941, Dr. Saul Hertz administered the very first radioactive iodine therapy to a patient with Graves' Disease. This pivotal treatment was the index case for what we today know as radioactive iodine therapy for hyperthyroidism, and it validated the concept that is now known as theranostics.
  • March 22, 2018Societies Collaborate to Address Differentiated Thyroid Cancer
    Representatives of SNMMI, the European Association of Nuclear Medicine (EANM), the European Thyroid Association (ETA) and American Thyroid Association (ATA) met at the Multilateral Conference on Differentiated Thyroid Cancer and began working collaboratively on issues related to the care of patients with thyroid cancer, with particular focus on radioactive iodine (RAI) therapy.
  • March 5, 2018Novel PET Imaging Agent Targets Copper in Tumors, Allowing Early Detection of Prostate Cancer Recurrence
    An Italian study featured in the March issue of The Journal of Nuclear Medicine demonstrates that a novel nuclear medicine imaging agent targeting copper accumulation in tumors can detect prostate cancer recurrence early in patients with biochemical relapse (rising prostate-specific antigen [PSA] level).

Preclinical Imaging

CMIIT’s mission is to engage the molecular imaging community and leverage the SNMMI infrastructure to advance the adoption of emerging molecular imaging technologies and probes in preclinical and clinical applications. One of the goals is to develop educational resources for a “translational researcher”. CMIIT will provide researchers with needed education and training on the “nuts and bolts” of translating and transitioning an agent or technique from pre-clinical research into the clinical practice such as tracer development, equipment, and funding.

The Nuclear Medicine Clinical Trial Group, LLC

Under the auspices of the Society of Nuclear Medicine and Molecular Imaging, the Nuclear Medicine Clinical Trial Group(NMCTG) assists industry partners and academic investigators in managing clinical research activities.  Its goals include ensuring quality imaging is conducted in drug or diagnostic clinical trials and providing training for molecular imaging professionals performing clinical research. Many of the programs established under the Clinical Trials Network, such as its robust Education Program, provide support to the NMCTG to help carry out its mission.